Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by Empowered Funds LLC

Empowered Funds LLC raised its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 5.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 266,838 shares of the company’s stock after acquiring an additional 13,534 shares during the quarter. Empowered Funds LLC’s holdings in Pediatrix Medical Group were worth $3,093,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Rubric Capital Management LP increased its stake in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. raised its stake in shares of Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares in the last quarter. Boston Partners lifted its holdings in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group during the second quarter worth $1,721,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insider Buying and Selling

In related news, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,808 shares of company stock worth $751,277. 2.00% of the stock is owned by corporate insiders.

Pediatrix Medical Group Stock Up 2.3 %

MD stock opened at $14.47 on Tuesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company’s 50 day simple moving average is $12.61 and its 200-day simple moving average is $9.89. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The firm has a market capitalization of $1.24 billion, a PE ratio of -4.73, a P/E/G ratio of 2.03 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. Equities analysts expect that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on MD. Jefferies Financial Group raised their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.